Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients with Neuroblastoma

Currently, patients with neuroblastoma are classified into risk groups (e.g., according to the Children’s Oncology Group risk-stratification) to guide physicians in the choice of the most appropriate therapy. Despite this careful stratification, the survival rate for patients with high-risk neuroblastoma remains <30%, and it is not possible to predict which of these high-risk patients will survive or succumb to the disease. Therefore, we have performed gene expression profiling using cDNA microarrays containing 42,578 clones and used artificial neural networks to develop an accurate predictor of survival for each individual patient with neuroblastoma. Using principal component analysis we found that neuroblastoma tumors exhibited inherent prognostic specific gene expression profiles. Subsequent artificial neural network-based prognosis prediction using expression levels of all 37,920 good-quality clones achieved 88% accuracy. Moreover, using an artificial neural network-based gene minimization strategy in a separate analysis we identified 19 genes, including 2 prognostic markers reported previously, MYCN and CD44, which correctly predicted outcome for 98% of these patients. In addition, these 19 predictor genes were able to additionally partition Children’s Oncology Group-stratified high-risk patients into two subgroups according to their survival status (P = 0.0005). Our findings provide evidence of a gene expression signature that can predict prognosis independent of currently known risk factors and could assist physicians in the individual management of patients with high-risk neuroblastoma.

[1]  Holger Christiansen,et al.  Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. , 2002, Cancer cell.

[2]  S. Artavanis-Tsakonas,et al.  Notch Signaling : Cell Fate Control and Signal Integration in Development , 1999 .

[3]  P. Waber,et al.  N-myc oncogene RNA expression in neuroblastoma. , 1988, Journal of the National Cancer Institute.

[4]  H. Nakamura,et al.  Regulation of the neural crest cell fate by N-myc: promotion of ventral migration and neuronal differentiation. , 1997, Development.

[5]  Carol A Barnes,et al.  Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites , 1995, Neuron.

[6]  C. Sotiriou,et al.  Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. , 2002, The Journal of molecular diagnostics : JMD.

[7]  M. Schwab,et al.  Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. , 1990, Cancer research.

[8]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[9]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[10]  Neuroblastoma Profiling and Artificial Neural Networks for Patients with Prediction of Clinical Outcome Using Gene Expression , 2004 .

[11]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[12]  D.,et al.  Regression Models and Life-Tables , 2022 .

[13]  Barbara Hero,et al.  Neuroblastoma: biology and molecular and chromosomal pathology. , 2003, The Lancet. Oncology.

[14]  K. Matsumoto,et al.  Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. , 1995, Cancer research.

[15]  P. Haber,et al.  Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Cantor,et al.  Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. , 1993, The New England journal of medicine.

[17]  D. Simon,et al.  Transient and restricted expression during mouse embryogenesis of Dll1, a murine gene closely related to Drosophila Delta. , 1995, Development.

[18]  E. Schuman,et al.  Dendrites , 1978, Journal of the Geological Society.

[19]  M Schwab,et al.  Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[20]  B. Korf,et al.  myc gene amplification and expression in primary human neuroblastoma. , 1990, Cancer research.

[21]  S. Sakano,et al.  Cloning and expressions of three mammalian homologues of Drosophila slit suggest possible roles for Slit in the formation and maintenance of the nervous system. , 1998, Brain research. Molecular brain research.

[22]  D. G. Altman,et al.  Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.

[23]  Y. Chen,et al.  Ratio-based decisions and the quantitative analysis of cDNA microarray images. , 1997, Journal of biomedical optics.

[24]  R. Bast,et al.  Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. , 2003, Cancer research.

[25]  F. Westermann,et al.  Genetic parameters of neuroblastomas. , 2002, Cancer letters.

[26]  N. Lee,et al.  A concise guide to cDNA microarray analysis. , 2000, BioTechniques.

[27]  B. Fervers,et al.  Induction chemotherapy in metastatic neuroblastoma--does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC). , 2000, European journal of cancer.

[28]  K. Boon,et al.  SAGE analysis of neuroblastoma reveals a high expression of the human homologue of the Drosophila Delta gene. , 2000, Medical and pediatric oncology.

[29]  L. Looi,et al.  CD44s expression correlated with the International Neuroblastoma Pathology Classification (Shimada system) for neuroblastic tumours , 2003, Pathology.

[30]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[31]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[32]  Michael L. Bittner,et al.  Ratio statistics of gene expression levels and applications to microarray data analysis , 2002, Bioinform..

[33]  D. Frappaz,et al.  Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J W Gray,et al.  NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Baylin,et al.  Molecular markers of neuroendocrine development and evidence of environmental regulation. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[37]  M. Ringnér,et al.  Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks , 2001, Nature Medicine.

[38]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  P. Pizzo,et al.  Principles and Practice of Pediatric Oncology , 1989 .

[40]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[41]  E. Lander,et al.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.